Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Dose-finding Randomized, Single-center, Double-blind, Placebo-controlled Safety and Immunogenicity Trial of the Vesicular Stomatitis Virus-vectored Zaire Ebola Candidate Vaccine BPSC1001 (VSVΔG-ZEBOV) in Healthy Adults.

NCT02287480 is registered in ClinicalTrials.gov with University Hospital, Geneva as lead sponsor.

NCT NCT02287480
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02287480 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Dose-finding Randomized, Single-center, Double-blind, Placebo-controlled Safety and Immunogenicity Trial of the Vesicular Stomatitis Virus-vectored Zaire Ebola Candidate Vaccine BPSC1001 (VSVΔG-ZEBOV) in Healthy Adults.
Lead sponsor
University Hospital, Geneva
Phase
Phase 1/2
Overall status
Completed
Start date
November 30, 2014
Completion date
January 31, 2016
Enrollment
115 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ebolavirus disease